Cardiol Therapeutics (CRDL) vs Molecular Partners (MOLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cardiol Therapeutics (CRDL) has outperformed Molecular Partners (MOLN) over the past year, losing 11.3% versus a loss of 37.5%. Over five years, CRDL leads with a -60.1% price change compared with -77.9% for MOLN. Cardiol Therapeutics is the larger company by market cap ($110.1 million vs $96.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRDL | MOLN |
|---|---|---|
| Share price | $0.8626 | $2.53 |
| Market cap | $110.14M | $96.80M |
| 1-day change | -2.28% | -5.25% |
| YTD return | -9.58% | -42.07% |
| 1-year return | -11.35% | -37.50% |
| 5-year return | -60.06% | -77.87% |
| EPS (TTM) | $-0.24 | $-1.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.34 | $5.36 |
| 52-week low | $0.8417 | $2.52 |
| Distance from 52-week high | -63.14% | -52.89% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +874.96% | +295.64% |
| Average volume | 1.20M | 1.63K |
| Shares outstanding | 127.69M | 38.34M |
| Employees | 18 | 134 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRDL has outperformed MOLN by 26.2 percentage points over the past year.
About Cardiol Therapeutics
CRDL stock →Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
About Molecular Partners
MOLN stock →Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees
CRDL vs MOLN FAQ
Which is bigger, Cardiol Therapeutics or Molecular Partners?
Cardiol Therapeutics (CRDL) is larger, with a market capitalization of $110.14M compared with $96.80M for Molecular Partners (MOLN).
Which stock has performed better over the past year, CRDL or MOLN?
CRDL returned -11.35% over the past 12 months, compared with -37.50% for MOLN (price return, excluding dividends). Past performance does not predict future results.
Are Cardiol Therapeutics and Molecular Partners in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.